Combination of targeted therapy and immune checkpoint blocker in a patient with xeroderma pigmentosum presenting an aggressive angiosarcoma and a recurrent non-resectable basal cell carcinoma

Eur J Cancer. 2021 Jun:150:130-132. doi: 10.1016/j.ejca.2021.03.022. Epub 2021 Apr 23.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anilides / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Carcinoma, Basal Cell / diagnostic imaging
  • Carcinoma, Basal Cell / drug therapy*
  • Carcinoma, Basal Cell / pathology
  • Compassionate Use Trials
  • Hemangiosarcoma / diagnostic imaging
  • Hemangiosarcoma / drug therapy*
  • Hemangiosarcoma / pathology
  • Humans
  • Immune Checkpoint Inhibitors / adverse effects
  • Immune Checkpoint Inhibitors / therapeutic use*
  • Male
  • Molecular Targeted Therapy
  • Neoplasm Recurrence, Local*
  • Nivolumab / therapeutic use*
  • Pyridines / therapeutic use*
  • Skin Neoplasms / diagnostic imaging
  • Skin Neoplasms / drug therapy*
  • Skin Neoplasms / pathology
  • Treatment Outcome
  • Xeroderma Pigmentosum / diagnostic imaging
  • Xeroderma Pigmentosum / drug therapy*
  • Xeroderma Pigmentosum / pathology

Substances

  • Anilides
  • HhAntag691
  • Immune Checkpoint Inhibitors
  • Pyridines
  • Nivolumab